203 related articles for article (PubMed ID: 37895233)
1. Detection of Cancer-Associated Gene Mutations in Urinary Cell-Free DNA among Prostate Cancer Patients in South Africa.
Temilola DO; Wium M; Paccez J; Salukazana AS; Rotimi SO; Otu HH; Carbone GM; Kaestner L; Cacciatore S; Zerbini LF
Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895233
[TBL] [Abstract][Full Text] [Related]
2. Seminal Cell Free DNA Concentration Levels Discriminate Between Prostate Cancer and Benign Prostatic Hyperplasia.
Ponti G; Maccaferri M; Micali S; Manfredini M; Milandri R; Bianchi G; Pellacani G; Kaleci S; Chester J; Conti A; Del Prete C; Tomasi A
Anticancer Res; 2018 Sep; 38(9):5121-5125. PubMed ID: 30194158
[TBL] [Abstract][Full Text] [Related]
3. Methylation pattern of caveolin-1 in prostate cancer as potential cfDNA biomarker.
Škara L; Vodopić T; Pezelj I; Abramovic I; Vrhovec B; Vrtarić A; Sincic N; Tomas D; Bulimbašić S; Kuliš T; Ulamec M
Biomol Biomed; 2023 Feb; 23(1):176-186. PubMed ID: 36036057
[TBL] [Abstract][Full Text] [Related]
4. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort.
Adeola HA; Smith M; Kaestner L; Blackburn JM; Zerbini LF
Oncotarget; 2016 Mar; 7(12):13945-64. PubMed ID: 26885621
[TBL] [Abstract][Full Text] [Related]
5. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
6. Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways.
White JA; Kaninjing ET; Adeniji KA; Jibrin P; Obafunwa JO; Ogo CN; Mohammed F; Popoola A; Fatiregun OA; Oluwole OP; Thorpe RJ; Karanam B; Elhussin I; Ambs S; Tang W; Davis M; Polak P; Campbell MJ; Brignole KR; Rotimi SO; Dean-Colomb W; Odedina FT; Yates C
Prostate; 2024 Apr; 84(5):460-472. PubMed ID: 38192023
[TBL] [Abstract][Full Text] [Related]
7. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
Su Z; Wang G; Li L
Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel candidate urinary protein biomarkers for prostate cancer in a multiethnic cohort of South African patients via label-free mass spectrometry.
Adeola HA; Soares NC; Paccez JD; Kaestner L; Blackburn JM; Zerbini LF
Proteomics Clin Appl; 2015 Jun; 9(5-6):597-609. PubMed ID: 25708745
[TBL] [Abstract][Full Text] [Related]
9. Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis.
Ponti G; Maccaferri M; Manfredini M; Micali S; Torricelli F; Milandri R; Del Prete C; Ciarrocchi A; Ruini C; Benassi L; Bettelli S; Kaleci S; Ozben T; Tomasi A
Clin Chim Acta; 2019 Oct; 497():76-80. PubMed ID: 31301282
[TBL] [Abstract][Full Text] [Related]
10. Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.
Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Kageyama R; Wells DK; Chan JM; Friedlander T; Aggarwal R; Paris PL; Feng F; Carroll PR; Witte JS
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250416
[TBL] [Abstract][Full Text] [Related]
11. A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer.
Cario CL; Chen E; Leong L; Emami NC; Lopez K; Tenggara I; Simko JP; Friedlander TW; Li PS; Paris PL; Carroll PR; Witte JS
BMC Cancer; 2020 Aug; 20(1):820. PubMed ID: 32859160
[TBL] [Abstract][Full Text] [Related]
12. Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study.
Guan Y; Wang X; Guan K; Wang D; Bi X; Xiao Z; Xiao Z; Shan X; Hu L; Ma J; Li C; Zhang Y; Shou J; Wang B; Qian Z; Xing N
BMC Med Genomics; 2022 May; 15(Suppl 2):104. PubMed ID: 35513884
[TBL] [Abstract][Full Text] [Related]
13. Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.
Yan C; Kim YH; Kang HW; Seo SP; Jeong P; Lee IS; Kim D; Kim JM; Choi YH; Moon SK; Yun SJ; Kim WJ
J Korean Med Sci; 2015 Dec; 30(12):1784-92. PubMed ID: 26713053
[TBL] [Abstract][Full Text] [Related]
14. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
15. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
Jin W; Fei X; Wang X; Chen F; Song Y
J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
[TBL] [Abstract][Full Text] [Related]
16. p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer.
Schlechte H; Lenk SV; Löning T; Schnorr D; Rudolph BD; Ditscherlein G; Loening SA
Eur Urol; 1998; 34(5):433-40. PubMed ID: 9803007
[TBL] [Abstract][Full Text] [Related]
17. Detection of Loss of Heterozygosity (LOH) Using Circulating Cell-free DNA (cfDNA) by Fluorescence-based Multiplex PCR for Identification of Patients With Prostate Cancer.
Seyedolmohadessin SM; Akbari MT; Nourmohammadi Z; Basiri A; Pourmand G
Appl Immunohistochem Mol Morphol; 2018; 26(10):749-759. PubMed ID: 28362710
[TBL] [Abstract][Full Text] [Related]
18. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.
Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Chu C; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Chan JM; Friedlander T; Wyatt AW; Aggarwal R; Paris PL; Carroll PR; Feng F; Witte JS
Sci Rep; 2021 Mar; 11(1):5040. PubMed ID: 33658587
[TBL] [Abstract][Full Text] [Related]
19. Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen.
Feng J; Gang F; Li X; Jin T; Houbao H; Yu C; Guorong L
Int Urol Nephrol; 2013 Aug; 45(4):1023-8. PubMed ID: 23779229
[TBL] [Abstract][Full Text] [Related]
20. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
Zhao H; Zhao X; Lei T; Zhang M
Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
